

Glenmark unveils Tenueligliptin + Pioglitazone combo drug for Type 2 diabetes in India

25 April 2022 | News

The combination will help to improve glycemic control among adult patients with insulin resistance



Glenmark Pharmaceuticals has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Tenueligliptin, with Pioglitazone.

This is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled Type 2 diabetes.

Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Tenueligliptin (20 mg) + Pioglitazone (15 mg), to be taken once a day.

The combination of Tenueligliptin + Pioglitazone will provide a synergistic approach wherein Tenueligliptin will optimally improve β cell sensitivity, and Pioglitazone will effectively reduce insulin resistance.

Glenmark is the first company in India to market the innovative FDC of Tenueligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India). This fixed dose combination will be useful for patients who require treatment with Tenueligliptin and Pioglitazone (as separate drugs) to improve glycemic control reducing insulin resistance.